ZG006 for advanced neuroendocrine prostate cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, ZG006, for men with advanced neuroendocrine prostate cancer that has worsened after platinum-based chemotherapy or caused serious side effects. The goal is to see if ZG006 can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 80 years.
- You have advanced neuroendocrine prostate cancer that has spread to other parts of the body.
- Your cancer got worse after at least one round of platinum-based chemotherapy, or you had to stop it due to side effects.
- You have tumors that can be measured on scans (CT or MRI).
- You are able to do daily activities with little or no help (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.
This trial tests a new drug called ZG005 in people with advanced solid tumors that have not spread to the brain. It aims to see if the drug is safe and can help shrink tumors.
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This trial tests a new drug (ZG005) combined with two standard chemotherapy drugs (etoposide and cisplatin) for people with advanced neuroendocrine carcinoma that has spread or come back. The goal is to see if the combination works better than the standard treatment alone.
Hear when a new Neuroendocrine Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.